DBV Technologies Announces Collaboration With The French National Genotyping Center

Wed, 04/09/2014 - 11:42am
Associated Press

BAGNEUX, France - DBV Technologies (Euronext: DBV - ISIN: FR0010417345), creator of Viaskin®, a new paradigm for the treatment of allergies, announced today a research collaboration agreement with the French National Genotyping Center (CNG) at the French Alternative energies and atomic energy commission (CEA). Dr. J. Tost's team at CNG uses novel technologies to analyze gene regulation and epigenetics, specifically DNA methylation. DBV and CEA/CNG will collaborate to characterize the epigenetic modifications induced by DBV's proprietary epicutaneous immunotherapy (EPITTM). The overall goal of the research is to understand the treatment maintenance effect over time and the predictive value of response to EPITTM treatment using Viaskin.

Preliminary experiments carried out by DBV have already demonstrated that EPIT may induce a modification of DNA methylation status. This was presented during the recent meeting of the American Academy of Allergy, Asthma & Immunology (AAAAI) in March 2014 and will be presented at the European Academy of Allergy andClinical Immunology (EAACI) in June 2014.



Share this Story

You may login with either your assigned username or your e-mail address.
The password field is case sensitive.